For a post-Soliris world, At­las-backed Q32 Bio out­lines $46M next-gen com­ple­ment play

Long be­fore Alex­ion kin­dled a re­nais­sance of com­ple­ment ther­a­peu­tics with the in­tro­duc­tion of the first an­ti-C5 an­ti­body, Mike Holers — a long­time pro­fes­sor at the Uni­ver­si­ty of Col­orado School of Med­i­cine — be­came fas­ci­nat­ed with the host de­fense sys­tem as he com­plet­ed his rheuma­tol­ogy train­ing. As Soliris be­gins to fade and fol­low-on, ri­vals and even gener­ics catch up to the stan­dard bear­er. Holers is de­but­ing a next-gen­er­a­tion ap­proach he’s been re­fin­ing with At­las Ven­ture over the last two years.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER